Lord Amy, Samuel Vasanth Mark, Kung Victor, Di Fabio Francesco, Cecil Tom, Dayal Sanjeev, Mohamed Faheez, Tzivanakis Alex, Moran Brendan
The Peritoneal Malignancy Institute, Basingstoke, UK.
Ann Surg Oncol. 2025 Jan;32(1):192-198. doi: 10.1245/s10434-024-15880-y. Epub 2024 Aug 8.
The role of gastrectomy to achieve complete cytoreduction (CCR) for pseudomyxoma peritonei (PMP) is controversial due to uncertain risk/benefit ratio. The outcomes of patients who gastrectomy over a twenty-year period in a high-volume unit are reported.
All patients requiring gastrectomy to achieve CCR for appendiceal PMP between 2000 and 2020 were reviewed. Demographics, disease, operative, complication, and survival data were analysed. The first and second decades were compared.
A total of 2148 patients underwent CRS and HIPEC, of which 78% had CCR. Gastrectomy was performed in 7.1%. Median age was 55 years, and 52% were female. Among gastrectomy patients, 94.2% had ≥1 elevated tumour marker, and 18% had high-grade disease. Median PCI was 30, and 30% required subtotal colectomy. Clavien-Dindo III-IV complications occurred in 32%, and 90-day mortality was 1.75%. Median survival was 104 months, and 10-year OS was 47%. Comparing the two decades, total CRS cases almost tripled, with a greater proportion achieving CCR (82.2% vs. 67.8%) but fewer requiring gastrectomy (5.3% vs. 13.5%). In those who had gastrectomy, disease was more advanced (higher PCI, more high-grade disease, more colectomies) in the later period. However, on multivariable analysis, there was no difference in survival between decades. High-grade histology was the only predictor of survival.
Gastrectomy can achieve good long-term survival with low mortality and acceptable morbidity and should not deter surgeons from achieving CCR. However, increasing experience shows CCR can be achieved, preserving the stomach in the majority of cases through careful consideration of the anatomy and gastric blood supply.
由于风险/收益比不确定,胃切除术在实现腹膜假黏液瘤(PMP)完全细胞减灭(CCR)中的作用存在争议。本文报告了一家大型医疗单位20年间接受胃切除术患者的治疗结果。
回顾了2000年至2020年间所有因阑尾PMP需要行胃切除术以实现CCR的患者。分析了人口统计学、疾病、手术、并发症和生存数据,并对第一个十年和第二个十年进行了比较。
共有2148例患者接受了细胞减灭术(CRS)和腹腔热灌注化疗(HIPEC),其中78%实现了CCR。7.1%的患者接受了胃切除术。中位年龄为55岁,52%为女性。在接受胃切除术的患者中,94.2%的患者肿瘤标志物≥1项升高,18%的患者为高级别疾病。中位腹膜癌指数(PCI)为30,30%的患者需要行结肠次全切除术。Clavien-Dindo III-IV级并发症发生率为32%,90天死亡率为1.75%。中位生存期为104个月,10年总生存率为47%。比较两个十年,CRS病例总数几乎增加了两倍,实现CCR的比例更高(82.2%对67.8%),但需要胃切除术的患者更少(5.3%对13.5%)。在接受胃切除术的患者中,后期疾病进展更严重(PCI更高、高级别疾病更多、结肠切除术更多)。然而,多变量分析显示,两个十年间生存率无差异。高级别组织学是生存的唯一预测因素。
胃切除术可实现良好的长期生存,死亡率低,发病率可接受,不应阻碍外科医生实现CCR。然而,经验的增加表明,通过仔细考虑解剖结构和胃血供,大多数情况下可以在保留胃的同时实现CCR。